The Pulse
Enveda Raises $311M to Advance AI-Discovered Drugs
Enveda has raised $311 million in Series E funding at a $2 billion valuation to advance three AI-discovered drug candidates. The Boulder biotech will use the money to move programs for eczema, metabolic health and inflammatory bowel disease
AI.info Team ·
Enveda has raised $311 million to move three AI-discovered drug candidates deeper into human testing, placing a large bet on molecules found in plants, microbes and other living systems rather than designed entirely from scratch.
The Boulder, Colorado-based biotech said on September 23, 2026, that Catalio Capital Management led its Series E financing. The round values Enveda at $2 billion, according to TechCrunch, roughly double the valuation the company reached a year earlier. Enveda said the financing brings its total capital raised since founding to more than $845 million.
The funding arrives with a tension familiar to AI drug developers: Enveda has generated positive early clinical data, but none of its candidates has regulatory approval. The company now has to show that its platform can produce medicines that survive the expensive, failure-prone stages between an encouraging Phase 1 result and a marketable drug.
Enveda’s $311M Round Targets Three Clinical Programs
Enveda plans to use the proceeds to advance ENV-294 and ENV-308 into later-stage trials and additional indications, move ENV-6946 through mid-stage development, and bring more candidates into clinical testing for inflammatory and metabolic conditions.
ENV-294 is an oral treatment being developed for atopic dermatitis and asthma. Enveda says a Phase 1b study found that eczema severity improved by an average of 85% after 42 days, with no serious side effects reported. Phase 2 trials are underway, and the company plans to present additional data at the European Academy of Dermatology and Venereology Congress on October 1, 2026.
ENV-308 is aimed at helping people maintain weight loss after stopping GLP-1 medicines. Enveda describes the drug as being inspired by a natural molecule released by the body during intense exercise. The company says the candidate was well tolerated in 88 healthy volunteers and showed a favorable gastrointestinal side-effect profile.
ENV-6946 is an oral treatment for inflammatory bowel disease that targets multiple inflammatory pathways. The candidate is currently in Phase 1 testing, according to Enveda.
PRISM Searches Chemistry That Conventional Screening Misses
Enveda’s platform, called PRISM, uses AI to identify molecules produced by plants, microbes and the human body, predict their structures from mass spectrometry data, guide laboratory experiments and rank compounds by therapeutic potential.
The company’s chemists then refine selected molecules into drug candidates. Enveda says the approach has produced 17 development candidates since 2019, with three now in human trials.
“We started Enveda on a different premise: the most reliable source of new medicines is the chemistry that living things have been refining for billions of years, and AI finally lets us read it,” Viswa Colluru, Enveda’s founder and chief executive, said in the financing announcement.
Colluru said the new capital would help Enveda build a company capable of carrying its medicines “from discovery through late-stage development” while moving faster and at lower cost than the company says the pharmaceutical industry has accepted.
Investors Back a Platform Before Any Approval
Catalio Capital Management led the round, which included new investment from Durable Capital Partners, ICONIQ, Lightspeed, Surveyor Capital, accounts advised by T. Rowe Price Investment Management, Digitalis Ventures, a sovereign wealth fund and Alderline Group.
Existing investors including Baillie Gifford, Premji Invest, FPV Ventures, True Ventures, Kinnevik, Dimension, Lifeforce Capital and Lux Capital also participated. George Petrocheilos, Catalio’s co-founder and managing partner, joined Enveda’s board as part of the financing.
“We invest at the intersection of biotech and AI because we believe the combination will change how medicines are discovered, and Enveda is one of the clearest cases of that actually happening,” Petrocheilos said.
Alex Gorsky, a general partner at ICONIQ, co-founder of Alderline Group and former chief executive of Johnson & Johnson, said Enveda’s pipeline progress and early clinical results influenced the investment.
The Next Test Is Clinical, Not Computational
Enveda’s financing gives it room to expand both its automated laboratory and the PRISM platform while pushing its first three clinical programs forward. The company has also recruited development leaders from Novo Nordisk, Madrigal Pharmaceuticals and LEO Pharma to support later-stage trials and potential commercialization.
Yet the company’s own financing announcement cautions that ENV-294, ENV-308 and ENV-6946 remain investigational agents. Early safety and efficacy signals can fail to predict later clinical outcomes, and the candidates still face regulatory review, additional trials and the possibility that they will not work in larger patient populations.
For now, Enveda’s strongest evidence is not an approved medicine but a pipeline: 17 candidates produced by its platform, three in human testing and two with early clinical readouts in 2026. The $311 million round will pay for the next set of results.